Yu Mizote
YOU?
Author Swipe
View article: Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routine EUS-FNA
Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routine EUS-FNA Open
Purpose To evaluate the in vitro drug sensitivity of patient-derived cancer organoids (PDCOs) established from residual samples from saline flushes (RSSF) collected during routine endoscopic ultrasound-guided fine-needle aspiration (EUS-FN…
View article: Relaxin-2-secreting CAR-T cells exhibit enhanced efficacy in stromal-rich xenograft tumors
Relaxin-2-secreting CAR-T cells exhibit enhanced efficacy in stromal-rich xenograft tumors Open
Introduction Chimeric antigen receptor (CAR)-T cell therapy has demonstrated notable efficacy in treating hematological malignancies. Although it has shown promise in the clinical management of solid tumors, poor outcomes in clinical trial…
View article: Roles of C-reactive protein and LOX-1 on cancer and myeloid-derived suppressor cells in the progression of uterine cervical cancer
Roles of C-reactive protein and LOX-1 on cancer and myeloid-derived suppressor cells in the progression of uterine cervical cancer Open
We investigated clinical implications of CRP and its receptor, LOX-1, in cervical cancer progression and the underlying mechanisms. Clinical data from 121 patients with cervical cancer administered definitive radiotherapy were analyzed to …
View article: Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG‐E8
Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG‐E8 Open
The direction and magnitude of immune responses are critically affected when dead cells are disposed of. Milk fat globule‐epidermal growth factor‐factor 8 (MFG‐E8) promotes the engulfment of apoptotic normal and cancerous cells without ind…
View article: Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids
Prediction for oxaliplatin‐induced liver injury using patient‐derived liver organoids Open
Background Liver injury associated with oxaliplatin (L‐OHP)‐based chemotherapy can significantly impact the treatment outcomes of patients with colorectal cancer liver metastases, especially when combined with surgery. To date, no definiti…
View article: Progressive Changes in the Protein Expression Profile of Alveolar Septa in Early-Stage Lung Adenocarcinoma
Progressive Changes in the Protein Expression Profile of Alveolar Septa in Early-Stage Lung Adenocarcinoma Open
Background Adenocarcinomas show a stepwise progression from atypical adenomatous hyperplasia (AAH) through adenocarcinoma in situ (AIS) to invasive adenocarcinoma (IA). Immunoglobulin superfamily containing leucine-rich repeat (ISLR) is a …
View article: Progressive Changes in Protein Expression Profile of Alveolar Septa in Early-Stage Lung Adenocarcinoma
Progressive Changes in Protein Expression Profile of Alveolar Septa in Early-Stage Lung Adenocarcinoma Open
Background Adenocarcinomas show a stepwise progression from atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS) and finally to invasive adenocarcinoma (IA). The expression of immunoglobulin superfamily containing leucine…
View article: Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells
Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells Open
Mannose has anticancer activity that inhibits cell proliferation and enhances the efficacy of chemotherapy. How mannose exerts its anticancer activity, however, remains poorly understood. Here, using genetically engineered human cancer cel…
View article: Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
View article: Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Supplementary Table 1A. Patient characteristics (n=145). Supplementary Table 1B. EGFR mutation types (n=44). Supplementary Table 2A. Univariate Cox regression analysis. Supplementary Table 2B. Multivariate Cox regression analysis.
View article: Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Representative results of analyses of CD4 (A) and CD8 (B) T cells expressing T cell activation and inhibitory molecules in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU456 by FACS.
View article: Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
OS of the advanced lung adenocarcinoma patients with different EGFR mutation types.
View article: Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
ICS of CD4 and CD8 T cells reactive against XAGE1 (GAGED2a).
View article: Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Correlation of OS with XAGE1 (GAGED2a) antibody titer in patients with XAGE1 (GAGED2a) antigen-positive tumors.
View article: Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Representative results of analyses on Th1, Th2, Th17 and TFH CD4 T cells, and resting and activated CD4 Tregs, and M- and PMN-MDSCs in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU213 or from an XAGE1 (GAGED2a) antibody-nega…
View article: Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
ICS of CD4 and CD8 T cells reactive against XAGE1 (GAGED2a).
View article: Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Correlation of OS with XAGE1 (GAGED2a) antibody titer in patients with XAGE1 (GAGED2a) antigen-positive tumors.
View article: Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
OS of the advanced adenocarcinoma patients with EGFRwt or EGFRmt tumors (A), and with XAGE1 (GAGED2a) antigen-positive EGFRwt or EGFRmt tumors and antibody, and XAGE1 (GAGED2a) antigen-negative EGFRmt tumors (B).
View article: Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Supplementary Table 1A. Patient characteristics (n=145). Supplementary Table 1B. EGFR mutation types (n=44). Supplementary Table 2A. Univariate Cox regression analysis. Supplementary Table 2B. Multivariate Cox regression analysis.
View article: Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Purpose: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarci…
View article: Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
View article: Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
OS of the advanced lung adenocarcinoma patients with different EGFR mutation types.
View article: Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
OS of the advanced adenocarcinoma patients with EGFRwt or EGFRmt tumors (A), and with XAGE1 (GAGED2a) antigen-positive EGFRwt or EGFRmt tumors and antibody, and XAGE1 (GAGED2a) antigen-negative EGFRmt tumors (B).
View article: Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Purpose: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarci…
View article: Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Representative results of analyses on Th1, Th2, Th17 and TFH CD4 T cells, and resting and activated CD4 Tregs, and M- and PMN-MDSCs in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU213 or from an XAGE1 (GAGED2a) antibody-nega…
View article: Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody Open
Representative results of analyses of CD4 (A) and CD8 (B) T cells expressing T cell activation and inhibitory molecules in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU456 by FACS.
View article: Author response: Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells
Author response: Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells Open
Full text Figures and data Side by side Abstract Editor's evaluation eLife digest Introduction Results Discussion Materials and methods Appendix 1 Data availability References Decision letter Author response Article and author information …
View article: Metabolic clogging of mannose triggers genomic instability via dNTP loss in human cancer cells
Metabolic clogging of mannose triggers genomic instability via dNTP loss in human cancer cells Open
Mannose has anti-cancer activity that inhibits cell proliferation and enhances the efficacy of chemotherapy. How mannose exerts its anti-cancer activity, however, remains poorly understood. Here, using genetically engineered human cancer c…
View article: Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer
Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic cancer Open
Background and study aims In patients with pancreatic cancer (PC), patient-derived organoid cultures can be useful tools for personalized drug selection and preclinical evaluation of novel therapies. To establish a less invasive method of …
View article: Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma Open
SMARCA4-deficient thoracic sarcoma (DTS) is a recently noted progressive thoracic malignancy. We recently experienced three cases of SMARCA4-DTS who were treated with atezolizumab in combination with bevacizumab, paclitaxel and carboplatin…